acute perforator artery cerebral infarction
Conditions
Interventions
experimental group:tilofiban bridges cilostazol and aspirin or clopidogrel
control group:Cilostazol combined with aspirin or clopidogrel
Sponsors
The First Hospital of Changsha
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: [1] Age range: 18-75 years old (inclusive); [2] Meets the diagnostic criteria for acute cerebral infarction and occurs within 24 hours of onset; [3] On diffusion-weighted imaging, common perforating arteries include the lentiform artery, the median pontine artery, the thalamic geniculate body artery, the anterior choroidal artery, the thalamic perforating artery, and other responsible blood vessels that innervate the corresponding infarcted lesions; [4] Diffusion weighted imaging shows a single infarction (maximum diameter = 15 mm or<30 mm) in the perforating artery area, involving two or more cross-sections, or connected to the ventral surface of the brainstem but not crossing the midline. [5] Vascular examination did not reveal significant arterial stenosis or occlusion, and cardiac evaluation ruled out evidence of cardioembolic embolism; [6] Provide informed consent from the patient or their representative.
Exclusion criteria
Exclusion criteria: [1] Functional impairment existed before the onset of the disease, with an mRS score greater than 2 points; [2] Imaging suggests that the carrier artery stenosis is greater than 70% or there are unstable plaques in the intracranial arteries, external carotid arteries, and vertebral arteries that can cause arterial arterial embolism; [3] Diffusion weighted imaging shows the presence of cortical infarction, watershed infarction, and multiple cerebral infarctions; [4] Cerebral infarction caused by other clear etiologies, such as immune or infectious vasculitis, cardioembolic stroke, fat embolism, platelet and coagulation dysfunction, etc. [5] Head CT shows intracranial hemorrhage and patients with a history of non traumatic intracranial hemorrhage; [6] Patients with a history of severe head trauma within the past 3 months; [7] Individuals who are allergic to tirofiban or have contraindications for the use of tirofiban (patients with active internal bleeding, history of intracranial hemorrhage, intracranial tumors, arteriovenous malformations, and giant intracranial aneurysms, as well as patients with thrombocytopenia who have previously used tirofiban); [8] Patients who cannot tolerate antithrombotic drugs such as aspirin enteric coated tablets, cilostazol, clopidogrel tablets, etc; [9] There has been gastrointestinal or urinary bleeding in the past 3 weeks; [10] Acute bleeding tendency, including platelet countthree times the upper limit of normal, severe renal dysfunction (creatinine clearance rate<30 mL/min), and an estimated survival time of less than 90 days in advanced malignant tumors); [13] Patients who cannot complete CT and MRI examinations (such as contrast agent allergies, pacemaker implantation, claustrophobia, etc.); [14] Patients currently participating in other clinical research trials; [15] Other situations identified by researchers as unsuitable for inclusion in clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NIHSS Score;mRS Score;BI Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-6;CRP;TNF-a; | — |
Countries
China
Contacts
Public ContactMiao Li
The First Hospital of Changsha
Outcome results
None listed